Myo vs D-chiro inositol
The two inositol isomers and why the 40:1 ratio is the PCOS canon
Definition
Inositol is a six-carbon cyclic polyol with nine stereoisomers, two of which are biologically relevant in humans: myo-inositol (MI), the most abundant form in tissues, and D-chiro-inositol (DCI), synthesized from MI by an insulin-dependent epimerase. Both act as second messengers in insulin, IGF-1 and FSH signaling, but with distinct roles: MI predominates in glucose uptake and oocyte quality, while DCI regulates androgen synthesis. In polycystic ovary syndrome (PCOS), the physiological plasma ratio of 40:1 is the therapeutic reference standard, and giving the isomers in the wrong balance can worsen rather than improve ovarian function.
Detailed explanation
The distinction between myo-inositol and D-chiro-inositol is load-bearing in metabolic and reproductive medicine. In plasma the MI:DCI ratio is roughly 40:1; in the healthy ovary it is even higher (up to 100:1). DCI is generated from MI by an insulin-activated epimerase. This gives rise to the "D-chiro-inositol paradox in the ovary" described by Carlomagno and Unfer: in PCOS, systemic hyperinsulinemia coexists with an ovary that retains insulin sensitivity, so the epimerase is locally over-stimulated, converts too much MI into DCI, and produces an ovarian MI deficiency that degrades oocyte quality.
Consequently, high-dose DCI alone worsens ovarian function and androgens, whereas replenishing MI — or combining both in the physiological 40:1 ratio (2 g MI + 50 mg DCI) — restores insulin and FSH signaling. Meta-analyses led by Vittorio Unfer (Sapienza, Rome) report improvements in ovulation, cycle regularity and HOMA-IR with this ratio. MI alone remains the form of choice for gestational diabetes, in-vitro fertilization and high-dose anxiety use; high-dose DCI monotherapy is contraindicated in PCOS.
Scientific sources
- PubMed — The D-chiro-inositol paradox in the ovary (Carlomagno, Unfer)
- PubMed — The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome (Unfer)
- PubMed — Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach (Facchinetti, Unfer)
- PubMed — Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of PCOS in a mouse model
Interested in related treatments?
Generate My Protocol